Effects of preset sequential administrations of sunitinib and everolimus on tumour differentiation in Caki-1 renal cell carcinoma

British Journal of Cancer

Volumn 112, Issue 1, 2015, Pages 86-94

  Dos Santos, C ^a,b   Tijeras Raballand, A ^a,b   Serova, M ^a,b   Sebbagh, S ^b   Slimane, K ^c   Faivre, S ^d   De Gramont, A ^a,d   Raymond, E ^b,d  

^a AAREC Filia Research   (France)

^b BEAUJON HOSPITAL   (France)

^c NOVARTIS PHARMA K K   (Japan)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

angiogenesis; EMT; kidney cancer; mTOR inhibitor; tyrosine kinase inhibitor

Indexed keywords

EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; S6 KINASE; SUNITINIB; UVOMORULIN; VIMENTIN; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE; RAPAMYCIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER SIZE; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEMALE; HYPOXIA; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; KIDNEY CARCINOMA; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION; TUMOR NECROSIS; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; CARCINOMA, RENAL CELL; CELL DIFFERENTIATION; DRUG ADMINISTRATION; DRUG EFFECTS; DRUG SCREENING; HUMAN; KIDNEY NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NUDE MOUSE; PATHOLOGY; VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; CELL DIFFERENTIATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PYRROLES; SIROLIMUS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84920657875     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.578     Document Type: Article

References (34)

1. Afonso FJ, Anido U, Fernandez-Calvo O, Vazquez-Estevez S, Leon L, Lazaro M, Ramos M, Anton-Aparicio L (2013) Comprehensive overview of the efficacy and safety of sorafenib in advanced or metastatic renal cell carcinoma after a first tyrosine kinase inhibitor. Clin Transl Oncol 15: 499.
2. Calvani N, Morelli F, Chiuri V, Gnoni A, Scavelli C, Fedele P, Orlando L, Maiello E, Lorusso V, Cinieri S (2013) Prolonged exposure to tyrosine kinase inhibitors or early use of everolimus in metastatic renal cell carcinoma: are the two options alike? Med Oncol 30: 578.
3. Chiatar SS, Eze OP, Schoenfeld AR (2013) Expression of VHL causes three-dimensional morphological changes in renal cells indicative of proximal tubule differentiation. Cell Dev Biol 2: e-pub ahead of print 12 August 2013; doi:10.4172/2168/9296.1000118.
4. Cockman ME, Masson N, Mole DR, Jaakkola P, Chang GW, Clifford SC, Maher ER, Pugh CW, Ratcliffe PJ, Maxwell PH (2000) Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 275: 25733-25741.
5. Cohen HT, McGovern FJ (2005) Renal-cell carcinoma. N Engl J Med 353: 2477-2490.
6. Creighton CJ, Morgan M, Gunaratne PH, Wheeler DA, Gibbs RA, Robertson A, Chu A, Beroukhim R, Cibulskis K (2013) Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499: 43-49.
7. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS (2009) Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15: 232-239.
8. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, Armand JP, Scigalla P, Raymond E (2006a) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24: 25-35.
9. Faivre S, Demetri G, Sargent W, Raymond E (2007) Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 6: 734-745.
10. Faivre S, Kroemer G, Raymond E (2006b) Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 5: 671-688.
11. Fuereder T, Jaeger-Lansky A, Hoeflmayer D, Preusser M, Strommer S, Cejka D, Koehrer S, Crevenna R, Wacheck V (2010) mTOR inhibition by everolimus counteracts VEGF induction by sunitinib and improves antitumor activity against gastric cancer in vivo. Cancer Lett 296: 249-256.
12. Gassenmaier M, Chen D, Buchner A, Henkel L, Schiemann M, Mack B, Schendel DJ, Zimmermann W, Pohla H (2013) CXC chemokine receptor 4 is essential for maintenance of renal cell carcinoma-initiating cells and predicts metastasis. Stem Cells 31: 1467-1476.
13. Gossage L, Murtaza M, Slatter AF, Lichtenstein CP, Warren A, Haynes B, Marass F, Roberts I, Shanahan SJ, Claas A, Dunham A, May AP, Rosenfeld N, Forshew T, Eisen T (2014) Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma. Genes Chromosomes Cancer 53: 38-51.
14. Hammers HJ, Verheul HM, Salumbides B, Sharma R, Rudek M, Jaspers J, Shah P, Ellis L, Shen L, Paesante S, Dykema K, Furge K, Teh BT, Netto G, Pili R (2010) Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study. Mol Cancer Ther 9: 1525-1535.
15. Huang B, Huang YJ, Yao ZJ, Chen X, Guo SJ, Mao XP, Wang DH, Chen JX, Qiu SP (2013) Cancer stem cell-like side population cells in clear cell renal cell carcinoma cell line 769 P. PLoS One 8: e68293.
16. Keisner SV, Shah SR (2011) Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs 71: 443-454.
17. Lane HA, Wood JM, McSheehy PM, Allegrini PR, Boulay A, Brueggen J, Littlewood-Evans A, Maira SM, Martiny-Baron G, Schnell CR, Sini P, O'Reilly T (2009) mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin Cancer Res 15: 1612-1622.
18. Larkin J, Esser N, Calvo E, Tsuchihashi Z, Fiedler U, Graeser R, Kim D (2012) Efficacy of sequential treatment with sunitinib-everolimus in an orthotopic mouse model of renal cell carcinoma. Anticancer Res 32: 2399-2406.
19. Ljungberg B, Bensalah K, Bex A, Canfield S, Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L, Merseburger AS, Mulders PFA, Staehler M, Volpe A (2013) EAU guidelines on renal cell carcinoma: the 2013 update. European assosiation of Urology. http://www.uroweb.org/gls/pdf/10-Renal-Cell-Carcinoma-LR.pdf.
20. Lu J, Cui Y, Zhu J, He J, Zhou G, Yue Z (2013) Biological characteristics of Rh123 stem-like cells in a side population of 786-O renal carcinoma cells. Oncol Lett 5: 1903-1908.
21. Makhov PB, Golovine K, Kutikov A, Teper E, Canter DJ, Simhan J, Uzzo RG, Kolenko VM (2012) Modulation of Akt/mTOR signaling overcomes sunitinib resistance in renal and prostate cancer cells. Mol Cancer Ther 11: 1510-1517.
22. Mikaelian I, Malek M, Gadet R, Viallet J, Garcia A, Girard-Gagnepain A, Hesling C, Gillet G, Gonzalo P, Rimokh R, Billaud M (2013) Genetic and pharmacologic inhibition of mTORC1 promotes EMT by a TGF-betaindependent mechanism. Cancer Res 73: 6621-6631.
23. Molina AM, Feldman DR, Voss MH, Ginsberg MS, Baum MS, Brocks DR, Fischer PM, Trinos MJ, Patil S, Motzer RJ (2012) Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. Cancer 118: 1868-1876.
24. Motzer RJ, Barrios CH, Kim TM, Falcon S, Cosgriff T, Harker WG, Pittman KB, Sabbatini R, Rha SY, Flaig TW, Page RD, Bavbek SE, Beck JT, Patel PM, Schiff E, Vaury A, Niolat J, Gogov S, Anak O, Knox J (2013) Record-3: Phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in patients with metastatic renal cell carcinoma (mRCC). In 2013 ASCO Annual meeting J Clin Oncol 31: 2765-2772.
25. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Kay A, Ravaud A (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116: 4256-4265.
26. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebocontrolled phase III trial. Lancet 372: 449-456.
27. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124.
28. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, Baselga J, Rosen N (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66: 1500-1508.
29. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D, Casanovas O (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15: 220-231.
30. Pugh CW, Ratcliffe PJ (2003) Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 9: 677-684.
31. Rosa R, Damiano V, Nappi L, Formisano L, Massari F, Scarpa A, Martignoni G, Bianco R, Tortora G (2013) Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer. Br J Cancer 109: 686-693.
32. Schoffski P, Dumez H, Clement P, Hoeben A, Prenen H, Wolter P, Joniau S, Roskams T, Van Poppel H (2006) Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review. Ann Oncol 17: 1185-1196.
33. Semenza GL (2013) HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J Clin Invest 123: 3664-3671.
34. Zhang Y, Sun B, Zhao X, Liu Z, Wang X, Yao X, Dong X, Chi J (2013) Clinical significances and prognostic value of cancer stem-like cells markers and vasculogenic mimicry in renal cell carcinoma. J Surg Oncol 108: 414-419.